rs376710410
Variant summary
Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PM1PM2PP2PP3_StrongPP5_Very_Strong
The NM_000404.4(GLB1):c.464T>G(p.Leu155Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000014 in 1,573,934 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000404.4 missense
Scores
Clinical Significance
Conservation
Publications
- GM1 gangliosidosisInheritance: AR Classification: DEFINITIVE Submitted by: Myriad Women’s Health, ClinGen
- GM1 gangliosidosis type 3Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp
- mucopolysaccharidosis type 4BInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, ClinGen, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- GM1 gangliosidosis type 1Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet
- GM1 gangliosidosis type 2Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 17 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000525 AC: 8AN: 152244Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000266 AC: 5AN: 188042 AF XY: 0.00000993 show subpopulations
GnomAD4 exome AF: 0.00000985 AC: 14AN: 1421690Hom.: 0 Cov.: 31 AF XY: 0.0000128 AC XY: 9AN XY: 703254 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000525 AC: 8AN: 152244Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74376 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Published functional studies found L155R is associated with significantly reduced beta-galactosidase activity (Hofer et al., 2009); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 17309651, 19472408, 20175788, 31761138, 33240792) -
- -
Mucopolysaccharidosis, MPS-IV-B Pathogenic:1
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
GM1 gangliosidosis;C0086652:Mucopolysaccharidosis, MPS-IV-B Pathogenic:1
This sequence change replaces leucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 155 of the GLB1 protein (p.Leu155Arg). This variant is present in population databases (rs376710410, gnomAD 0.006%). This missense change has been observed in individual(s) with GM1-gangliosidosis, type I (PMID: 17309651, 19472408, 20175788, 25557439). ClinVar contains an entry for this variant (Variation ID: 265179). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLB1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects GLB1 function (PMID: 19472408). For these reasons, this variant has been classified as Pathogenic. -
Mucopolysaccharidosis, MPS-IV-B;C0268271:Infantile GM1 gangliosidosis;C0268272:GM1 gangliosidosis type 2;C0268273:GM1 gangliosidosis type 3 Pathogenic:1
- -
Infantile GM1 gangliosidosis Other:1
Variant interpreted as Pathogenic and reported on 09-13-2014 by Lab or GTR ID 26957. GenomeConnect-GM1 assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at